Significance: Bazedoxifene (BZA) is a potent orally available antiestrogen that is clinically 26 approved for use in hormone replacement therapy (DUAVEE). We explore the efficacy of BZA 27 to inhibit activating somatic mutants of ERα that can arise in metastatic breast cancers after 28 prolonged exposure to aromatase inhibitors or tamoxifen therapy. Breast cancer cell line, 29 biophysical, and structural data show that BZA disrupts helix 12 of the ERα ligand binding 30 domain to achieve improved potency against Y537S and D538G somatic mutants compared to 4-31 hydroxytamoxifen.
eLife 5 improved inhibitory efficacy against the Y537S and D538G mutants in breast cancer cells. Table   106 1 shows the chemical structures of the molecules examined in this study and summarizes their 107 clinical indications. 108 Raloxifene (RAL) SERM  Osteoporosis in postmenopausal women [26] .  Reduction in Breast Cancer Incidence in High Risk Women [27] .
Fulvestrant (FULV)
SERD  First-line therapy for metastatic breast cancer [28] .  Postmenopausal women with progressive breast cancer following other antiestrogen therapy [29, 30] . treated with E2 plus 4-OHT, FULV, or BZA vehicle and normalized to E2. C) Relative c-myc mRNA 141 levelsMCF-7 cells treated with E2 plus 4-OHT, FULV, or BZA vehicle and normalized to E2. D) 142
Relative GREB1 mRNA levels in MCF-7 cells treated with E2 plus 4-OHT, FULV, or BZA vehicle and 143 normalized to E2. E) Relative CA12 mRNA levels of MCF-7 cells treated with E2 plus 4-OHT, FULV, 144 or BZA vehicle and normalized to E2. F) ERα degradation in MCF-7 cells with increasing doses of BZA 145
or FULV normalized to β-actin. G) Inhibition of cell growth with increasing concentrations of BZA, 146 FULV, BZA is a Potent Inhibitor of Activating Somatic Mutants of ERα in Breast Cancer Cells 148 We next tested the activity of BZA in MCF7 cells that ectopically expressed theY537S 149 mutant ERα to determine the inhibition of Y537S mutant cell growth. BZA demonstrated an 150 increased potency compared to FULV and 4-OHT, with an IC 50 of 1x10 -10 M vs 2x10 -9 M and 151 7x10 -9 M, respectively (Figure 2A) . In addition, qPCR data showed that BZA inhibited the 152 transcription of ERα target genes cyclin D1, c-Myc, and PR, in cells expressing the Y537S 153 mutant, in a dose-dependent manner, confirming the on-target effects of BZA in the presence of 154 the mutation (Figure 2B) . 155 To evaluate the ability of BZA to induce WT and mutant ERα degradation in breast 156 cancer cells, we treated MCF-7 cells that ectopically expressed HA-tagged WT, Y537S and 157 D538G ERα with BZA and other ligands for comparison. Levels of WT and mutant ERα were 158 quantified using immunoblots with an anti-HA antibody. Cells were treated with 10 nM E2, or 159 100 nM 4-OHT, 100 nM BZA, 100 nM RAL, 1 µM FULV or vehicle for 24 hours before 160 immunostaining; 1 µM FULV was chosen because it was the minimal concentration necessary to 161 achieve maximal ERα degradation. All data were normalized to vehicle-treated cells. In cells 162 expressing HA-WT ERα, BZA and FULV induced degradation of the receptor to similar levels 163 while the amount of the receptor increased upon 4-OHT treatment and was slightly reduced with 164 E2 and RAL (Figure 2C and D) . Interestingly, for the Y537S mutant, ERα expression remained 165 unchanged for E2 and FULV, while it increased for 4-OHT and RAL. Y537S ERα also 166 increased with BZA but less so than RAL or 4-OHT. Surprisingly, BZA degraded the D538G eLife 9 ERα mutant to a greater extent than FULV while 4-OHT and RAL both increased its expression 168 after 24 hours. It should be noted that BZA and FULV elicited consistent WT and mutant ERα 169 degradation across all replicates (Supplemental Figure 1) . Similarly, immunoblotting for ER showed that treatment with PB does not affect BZA or 198 FULV induced degradation of ERα ( Figure 3I) . In sum, these data show that dual inhibition of 199 CDK4/6 with PB and ERα with BZA is an effective combination with significant activity against 200 breast cancer cells expressing WT or constitutively active mutant ERα. [32], we tested the effects of 4-OHT, BZA and FULV on co-regulator binding. We applied the 214 Microarray Assay for Real-time Coregulator-Nuclear receptor Interaction (MARCoNI), which allows the quantification of binding affinity of a nuclear receptor with co-regulator peptides. To 216 determine the effect of 4-OHT, BZA and FULV on co-regulator binding to WT, Y537S and 217 D538G ERα, MCF7 cells that ectopically express HA-tagged WT, Y537S, or D538G ERα were 218 used in conjunction with an HA antibody to detect ER binding to the co-regulator array.
219
Experiments were performed under E2 stimulated conditions for WT ER and under apo 220 conditions for mutant ERα. Overall, dose-dependent inhibition of co-regulator binding was 221 observed for the majority of co-regulator peptides with the three drugs (Supplemental Figure   222 2A). A comparison of EC 50 levels for inhibition of co-regulator binding of the three ER 223 antagonists showed that EC 50 levels for FULV in both the WT and mutant cells was higher, as 224 expected given the mechanism of action of FULV, compared to SERMs. The 4-OHT and BZA 225 EC 50 s were higher in the presence of the Y537S and D538G mutations. Collectively, these 226 results show that differences in antagonistic activity manifested by the three endocrine treatments 227 are reflected by changes in co-regulator binding. There are significant differences among these 228 drugs in their antagonistic activity on WT-ER and mutant ER. Previously, we showed that in the absence of hormone, SRC3 did not bind to WT ERα 239 LBD, whereas Y537S ERα bound SRC3 markedly in the absence of E2 with a 10-fold reduced 240 affinity, and D538G ERα bound SRC3 with a 100-fold reduced affinity compared to hormone 241 bound WT receptor [8] . To better ascertain the potency of ligands to inhibit coactivator 242 recruitment, we titrated the ligands into fixed concentrations of LBD and SRC3 and monitored 243 LBD-SRC3 interaction by a FRET assay; the three samples were primed with E2 to get a 244 measurable signal from WT and D538G ER. 4-OHT, BZA and RAL reversed the binding of 245 SRC3 NRD to the two mutant ERs and WT-ERα with similar potencies (Supplemental Figure   246 2B). Together, these data show that BZA, 4-OHT, and RAL inhibit both the basal and E2-247 stimulated recruitment of SRC3 coregulator by the WT and mutant ERα in vitro.
248

BZA, RAL and FULV Elicit Similar Reduced Binding Affinities for Y537S and D538G
249 Compared to WT ERα LBD 250 To examine what role alterations in binding affinity may play in this reduced potency, 251 competitive [ 3 H]-E2 ligand binding assays ligand-binding experiments were used to examine the 252 effect of Y537S and D538G mutations on BZA, RAL, and FULV ER binding affinities in vitro. 253 We previously showed that the E2 and 4-OHT binding was significantly reduced for both the 254 Y537S and D538G mutants [8] . Affinities were reported using K i values calculated from IC 50 255 values using the Cheng-Prusoff equation ( Supplemental Table 2 ) [33] . The affinities of RAL,
256
BZA and FULV for the ERα mutants were reduced 9 to 27-fold relative to WT-ERα. It should be 257 noted that the binding affinity of 4-OHT remained the highest compared to RAL, BZA and 258 FULV against the mutant LBDs. The binding affinities of all tested antiestrogens were somewhat 259 more reduced in D538G than in Y537S. However, FULV and BZA demonstrated the highest 260 potencies in the transcriptional reporter gene assays, even though they exhibited reduced affinities compared to 4-OHT. Therefore, our data indicate that other factors beyond the reduced 262 binding affinity of mutant LBDs for SERM or SERD must play a role in their decreased potency.
263
The SERD Properties of BZA Arise from its Disruption of Helix 12 264 X-ray crystallography was used to reveal the structural details of BZA's antiestrogen 265 properties. An x-ray crystal structure for the WT ERα LBD, in complex with BZA was solved to 266 2.4 Å with two dimers in the asymmetric unit (ASU) (PDB: 4XI3). The BZA ligand and H12 are 267 well resolved in each monomer in the ASU; poorly resolved residues were not included in the suggests that the ketone on the RAL linker constrains the phenyl group, sterically precluding the 279 adoption of an ideal hydrogen bonding geometry with H524. The core differences for BZA 280 broadcast down the linker arm to alter its vector towards H12 where the azepan ring now pushes 281 against V534 and P535 (Figure 4B) . The alterations to V534 and P535 propagate to H12 which 282 appears displaced out of the AF-2 cleft into a less stable orientation. (Figure 5A) . Importantly, the energetic minima well is significantly broader for BZA 295 compared to RAL, indicating that the angles adopted by BZA in the ERα ligand-binding site are more favorable than RAL. Furthermore, an energetic penalty of approximately 1 kcal/mol would 297 be incurred by RAL to adopt the same conformation observed for BZA in the x-ray crystal 298 structure. Together these data show that the BZA ligand itself possesses physical properties that 299 are more favorable to impact ERα H12 compared to RAL. Unfortunately, we were unable to collect HDX data for the Y537S mutant with FULV because it 318 precipitated out of solution. Similar to previously published data [8] , binding of 4-OHT resulted in decreased stability of H12 with the Y537S compared to D538G and WT receptor 320 (Supplemental Figure 6 ), suggesting that these mutants resist the ability of the SERM to alter 321 their structure. Interestingly, addition of BZA did not increase the stability (lesser protection) of 322 the region near H12 to as great of an extent as 4-OHT in WT and mutant ERα LBDs, suggesting 323 that BZA-bound ERα adopts a less stable antagonist conformation than 4-OHT-bound ERα 324 (Supplemental Figure 7) , consistent with the crystal structure. These data suggest that, while (Figure 5B, D) . Furthermore, H12 conformational fluctuations 337 observed in MD simulations are less pronounced in Y537S-BZA than they are in D538G-BZA 338 (Figure 5C) , which echoes the aforementioned reduced H12 dynamics observed in HDX-MS 339 data and agrees with our result that Y537S reduces BZA activity more than D538G does. Over 340 the course of the simulations, the Y537S-BZA structure shows a hydrogen bond formation between E380 and S537 (Figure 5B) , which could contribute to fewer H12 conformational 342 fluctuations in Y537S ERα. It should be noted that this hydrogen bond is not sterically allowed 343 in the WT-BZA crystal structure. This predicted hydrogen bond may stabilize H12 in the AF-2 344 cleft relative to WT. The simulated H11-12 loop conformations for both Y537S-BZA and 345 D538G-BZA resemble WT-BZA or D538G-4-OHT, being closer to the ligand binding site, than 346 they do to WT-4-OHT. The D538G mutation further increases the conformational variance of 347 the H11-12 loop compared to Y537S (Figure 5C) , which can be explained by the lack of a 348 hydrogen bond in Y537S and the greater backbone conformational freedom allowed by the 349 mutant glycine residue. Additionally, the H11-12 loop of both Y537S and D538G appears 350 further away from the protein core and BZA compared to that of WT (Figure 5B, D) . We Somatic mutation to ESR1 following prolonged estrogen-deprivation therapy represents a 372 newly appreciated mechanism of acquired hormone resistance in metastatic breast cancer. The 373 two most prevalent mutations,Y537S and D538G, give rise to a dysfunctional receptor that 374 escapes hormone regulation and has decreased sensitivity to inhibition by 4-OHT and fulvestrant 375 [8] . Newly characterized orally available pure antiestrogens (e.g., GDC-0927, AZ9496, and 376 RAD1901) are emerging as potentially potent inhibitors of these mutants, but their long-term 377 clinical utility is unknown and their side effect profiles have not been studied in large patient 378 populations [12, 14] . Because BZA is already clinically approved for use in hormone 379 replacement therapy and is a potent ERα antagonist in the breast, an agonist in bone, and neutral 380 in the endometrium with long-term safety data in thousands of patients, we explored its ability to 381 inhibit the Y537S and D538G ERα somatic mutants in breast cancer [9] . 382 We first quantified the ability of BZA to disrupt WT and mutant ERα transcription, although not as destabilized as when FULV is bound.
407
Atomistic MD simulations were used to examine the molecular basis for the observed 408 decrease in degradation of ER within breast cancer cells expressing the Y537S and D538G 409 mutants. Both mutants stabilized the antagonist conformation of H12 in the AF-2 cleft, while the 410 Y537S appeared to be the more stable of the two by forming a hydrogen bond between S537 and 411 E380. Interestingly, E380Q has also been found to be a recurrent ESR1 mutation able to confer 412 endocrine resistance. MD simulations also suggest that these mutants have varied conformations 413 and increased dynamics of loop H11-12, which potentially reduces BZA's ability to disrupt ER 414 antagonist conformations. Together these results suggest that BZA retains its SERM antagonist 415 properties within breast cancer cells expressing Y537S and D538G mutant ERα to a greater eLife 22 extent than 4-OHT but its SERD-like properties are diminished. The reduced potency on the 417 mutants likely derives from the stabilization of the apo receptor in the agonist conformation, 418 which reduces the on rate of ligand binding [8] , reflecting that the agonist conformer blocks 419 ligand exchange [35] . 420 Overall, our findings show the molecular basis for the SERD-like activity of BZA and its 421 potential advantage with and without CDK4/6 inhibitor, versus 4-OHT, to inhibit the Y537S and 422 D538G ERα mutants. Importantly, interrogating the structural details of BZA-ERα LBD binding 423 suggests that molecules with improved pharmacological profiles that specifically disrupt the 424 H11-12 loop at H12 will have clear advantages against breast cancer cells expressing WT, 425 Y537S, and D538G ERα. The 6×His-TEV-tagged ERα-L372S, L536S double mutant LBD was expressed in E.coli 557 BL21(DE3) and purified as described [46] . LBD (10 mg/mL) and incubated with 1 mM BZA 558 overnight at 4 °C. LBD-BZA was crystallized using vapor diffusion by hanging drop in 33% 559 PEG 3,350, 100 mM Tris pH 6.6, and 250 mM MgCl 2 . Diffraction data were collected at the 560 Canadian Light Source at beamline 08ID-1 at a wavelength of 0.97 Å. Indexing, scaling, and 561 structure refinement were performed as described [8] . Supplemental Table 1 shows data 562 collection and refinement statistics. Final coordinates were deposited in the Protein Databank 563 with the accession code 4XI3.
564
Quantum Mechanical Calculations
565
Torsion scans were performed on the bond connecting the internal subsituents to the central core 566 for each ligand. The ligand coordinates were extracted from x-ray crystal structures of BZA 567 (PDB code 4XI3) and RAL (PDB code 2QXS) and all hydrogens were added. Relaxed potential 568 energy surface scans in which the remainder of the structure is geometry optimized at each 569 torsion step were prepared and analyzed using the torsion scan module of the Force Field Toolkit [50]. The remaining ligand parameterization was carried out as described [8] .
580
Structure preparation, molecular dynamics, data visualization and analysis. WT-BZA (PDB: 581 4XI3) was used as a template to construct starting structures of Y537S-BZA and D538G-BZA.
582
Specifically, chains A and C were chosen among the three dimers in 4XI3 for having the least 583 missing residues in the loop H11-12 region, with ions removed and water molecules retained.
584
Side chain atoms of mutation sites (residue 537 and 538, respectively) were also replaced with 585 the mutant residues. Otherwise, structures were prepared, molecular dynamics were calculated, 586 and data were analyzed/visualized as described [8] . Deuterium uptake for each peptide is calculated as the average of % D for the 6 time points (10s, 823 30s, 60s, 300s, 900s and 3600s), and the difference in average % D values between the Apo-ERα 824
and ERα-E2 bound samples is shown as a heat map with a color code given at the bottom of the 825 figure (warm colors for deprotection and cool colors for protection). Peptides are colored only if 826 they show a >5% difference (less or more protection) in average deuterium uptake between the 827 two states, and the software employs a paired two-tailed student's t-test-based coloring scheme 828 (p-value < 0.05 for two consecutive time points or a p-value < 0.01 for a single time point) to 829 distinguish real protection differences from inherent variation in the data. Grey color represents 830 no significant change (0-5%) between the two states. 831 832
